idose tr | Glaukos iDose® TR (travoprost intracameral implant) |

Keyword	CPC	PCC	Volume	Score	Length of keyword
idose tr	0.72	0.8	1432	56	8
idose	1.72	0.5	7366	83	5
tr	0.31	0.4	7690	1	2

Keyword	CPC	PCC	Volume	Score
idose tr	0.55	0.1	8783	25
idose travoprost	0.5	0.6	3381	77
idose tr 75 mcg	0.44	0.6	3893	9
idose tr implant	0.77	0.1	7565	56
glaukos idose tr	1.07	0.1	3960	53

Search Results related to idose tr on Search Engine

Glaukos iDose® TR (travoprost intracameral implant) | FDA …
idosetr.com

https://www.idosetr.com/

WEBGet to know iDose® TR a new way to lower eye pressure. iDose TR (travoprost intracameral implant) is an FDA-approved treatment that continuously releases medication to lower eye pressure. Stay connected for more information about iDose TR and helpful education along your glaucoma journey.

DA: 87 PA: 67 MOZ Rank: 73

iDose® TR | Glaukos
glaukos.com

https://www.glaukos.com/glaucoma/products/idose-tr/

WEBiDose TR is the first-of-its-kind, long duration, anchored intracameral procedural pharmaceutical therapy for the treatment of OAG or OHT. It delivers continuous prostaglandin analog therapy directly into the anterior chamber to help with long-term IOP control with proven safety and patient tolerability.

DA: 18 PA: 53 MOZ Rank: 88

Glaukos Announces FDA Approval of iDose® TR (travoprost …
businesswire.com

https://www.businesswire.com/news/home/20231214281849/en/Glaukos-Announces-FDA-Approval-of-iDose%C2%AE-TR-travoprost-intracameral-implant

WEBDec 14, 2023 · iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need. FDA approval based on...

DA: 12 PA: 57 MOZ Rank: 67

iDose® TR Prescribing Information | Glaukos
glaukos.com

https://www.glaukos.com/prescribing-information/idosetr/

WEBINDICATIONS AND USAGE. iDose ® TR is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) ( 1) DOSAGE AND ADMINISTRATION. For ophthalmic intracameral administration ( 2.1)

DA: 77 PA: 98 MOZ Rank: 2

Glaukos iDose® TR (travoprost intracameral implant)—FDA …
idosetrhcp.com

https://www.idosetrhcp.com/

WEBiDose TR delivers continuous long-term prostaglandin analog therapy directly into the anterior chamber for IOP control with proven safety and patient tolerability. iDose TR is an FDA-approved treatment indicated for the reduction of intraocular pressure (IOP) in patients with OAG or OHT.

DA: 83 PA: 19 MOZ Rank: 8

FDA approves travoprost intracameral implant
ophthalmologytimes.com

https://www.ophthalmologytimes.com/view/fda-approves-travoprost-intracameral-implant

WEBDec 14, 2023 · Glaukos Corp's iDose TR has received FDA approval for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) following a new drug application (NDA) submission.

DA: 20 PA: 96 MOZ Rank: 57

iDose: An Intraocular Drug-Eluting Delivery Device for Glaucoma
glaucomatoday.com

https://glaucomatoday.com/articles/2020-nov-dec/idose-an-intraocular-drug-eluting-delivery-device-for-glaucoma

WEBiDose: An Intraocular Drug-Eluting Delivery Device for Glaucoma - Glaucoma Today. The Pipeline | November/December 2020. iDose: An Intraocular Drug-Eluting Delivery Device for Glaucoma. A closer look at the device’s implantation, clinical trial findings, and outstanding questions. Mitch Ibach, OD, FAAO. Share: View PDF.

DA: 52 PA: 66 MOZ Rank: 88

Glaukos - Glaukos’ iDose®TR Demonstrates Sustained IOP …
glaukos.com

https://investors.glaukos.com/investors/news/news-details/2022/Glaukos-iDoseTR-Demonstrates-Sustained-IOP-Reduction-and-Favorable-Safety-Profile-Over-36-Months-in-Phase-2b-Study/default.aspx

WEBJan 11, 2022 · The Phase 3 trials randomized a total of 1,150 subjects across 89 clinical sites, the majority of which are in the United States. The 12-month iDose TR Phase 3 trial results are expected to support Glaukos’ targeted NDA submission in 2022 and FDA approval for iDose TR in 2023. About Glaukos

DA: 26 PA: 82 MOZ Rank: 48

FDA Approves iDose TR (travoprost intracameral implant) for the
drugs.com

https://www.drugs.com/newdrugs/fda-approves-idose-tr-travoprost-intracameral-implant-glaucoma-6160.html

WEBDec 14, 2023 · iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time.

DA: 5 PA: 16 MOZ Rank: 36

IDose TR: Uses, Dosage, Side Effects, Warnings - Drugs.com
drugs.com

https://www.drugs.com/idose-tr.html

WEBMar 26, 2024 · iDose TR is used to lower intraocular pressure (IOP) in patients who have ocular hypertension (OHT) or open-angle glaucoma (OAG). The increase in eye pressure in OAG can cause loss of peripheral vision followed by central field blindness and increase the risk of vision loss in OHT.

DA: 71 PA: 22 MOZ Rank: 38